​The indigenous CAR-T therapy has shown maximum efficacy against B-ALL and which other blood cancer?​

Correct option is A

The correct answer is (A) Non‑Hodgkin Lymphoma

Explanation:

• The indigenous (CD19-directed) CAR‑T therapy developed in India (such as NexCAR19 / IMN‑003A) is effective against B‑ALL and B‑cell Non‑Hodgkin Lymphoma (B‑NHL).
• Government sources explicitly state that the therapy is effective in “B‑ALL, and B‑Non‑Hodgkin Lymphoma (B‑NHL)” as the two main indications of maximum efficacy.
• CAR‑T approaches targeting CD19 are well established in B‑cell lymphomas globally.

Information Booster:

• Non‑Hodgkin Lymphoma (especially B‑cell subtype) expresses CD19 antigen, making it a suitable target for CD19 CAR‑T cells.
• CAR‑T in B‑NHL has shown high response rates in relapsed/refractory settings in multiple trials worldwide.
• The success in B‑ALL and B‑NHL underscores the “B‑cell malignancies” niche for CAR‑T therapy.
• Ongoing research is extending CAR‑T to other blood cancers (e.g. multiple myeloma) but with different antigen targets.

Additional Knowledge:

• Option B: Hodgkin Lymphoma — Generally lacks CD19 expression, making CD19 CAR‑T less effective.
• Option C: Chronic Myeloid Leukaemia — A myeloid (not B‑cell) malignancy; CD19 CAR‑T is not appropriate.
• Option D: Multiple Myeloma — Though CAR‑T is being explored (e.g. BCMA CAR‑T), the indigenous Indian CAR‑T primarily is for B‑cell cancers, not myeloma.